BD Resumes ChloraPrep Shipments Amid Ongoing FDA Review
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Becton Dickinson ( (BDX) ) just unveiled an update.
On May 6, 2026, BD voluntarily placed its ChloraPrep and PurPrep antiseptic products on ship hold in the U.S. while it carried out additional final release testing, a move linked to an FDA Warning Letter issued for the company’s El Paso manufacturing facility. The company has since resumed shipments of ChloraPrep in the U.S., reporting that all added final release tests to date have been acceptable and that no patient safety signals have been identified, helping to safeguard continuity of patient care while it addresses regulatory concerns.
The shipment resumption suggests that immediate supply disruptions for ChloraPrep have been mitigated, reducing near-term operational risk for BD’s customers that rely on the product in clinical settings. However, the underlying FDA Warning Letter for the El Paso plant continues to represent a regulatory overhang, and investors and health care providers are likely to watch closely how BD manages compliance issues and any broader implications for its manufacturing network and product portfolio.
The most recent analyst rating on (BDX) stock is a Hold with a $161.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
Spark’s Take on BDX Stock
According to Spark, TipRanks’ AI Analyst, BDX is a Neutral.
The score is driven by solid financial quality—especially strong free cash flow and improving leverage—plus supportive earnings-call guidance with raised adjusted EPS. These positives are tempered by weak technicals (price below key moving averages with negative MACD) and a less helpful valuation signal due to a negative P/E, alongside near-term operational headwinds (tariffs, China, and a temporary FDA-related shipment hold).
To see Spark’s full report on BDX stock, click here.
More about Becton Dickinson
Becton, Dickinson and Company is a global medical technology firm that develops and manufactures a broad range of medical supplies, devices, laboratory equipment and diagnostic products. The company focuses on supporting hospitals, clinics and other health care providers with tools that are critical to patient care and infection prevention in the U.S. and international markets.
Average Trading Volume: 2,827,647
Technical Sentiment Signal: Sell
Current Market Cap: $40.57B
For detailed information about BDX stock, go to TipRanks’ Stock Analysis page.
